PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 24, 2026SHILAP Revista de lepidopterología1 citationsOpen Access

Effectiveness and safety of ceftazidime/avibactam versus polymyxin B in liver transplant recipients with carbapenem-resistant organism infections: a real-world cohort study

View Full Paper
WZWei ZhangCCChuanlin ChenDLDesheng Li

Key Points

  • This research aims to compare the efficacy and safety of ceftazidime/avibactam versus polymyxin B in liver transplant recipients with carbapenem-resistant infections.
  • Single-center retrospective cohort analysis of liver transplant patients with CRO infections
  • Included patients received CAZ/AVI or PMB for over 48 hours
  • Used logistic regression and Cox proportional hazards models for analysis.
  • Microbial clearance rates were similar between CAZ/AVI and PMB groups (59.1% vs. 63.6%)
  • Clinical success was also comparable (54.6% vs. 54.6%)
  • PMB group had a significantly higher acute kidney injury rate (81.8% vs. 50.0%, p = 0.026).

Abstract

Background Treatment options for carbapenem-resistant organism (CRO) infections remain limited, with ceftazidime/avibactam (CAZ/AVI) and polymyxin B (PMB) being the main therapeutic choices. However, comparative evidence regarding the efficacy and safety of liver transplant (LT) recipients is scarce.Methods This single-center retrospective cohort study was conducted in the liver intensive care unit of Beijing Tsinghua Changgung Hospital from January 2018 to December 2024. Adult LT recipients with CRO infections who received intravenous CAZ/AVI or PMB for > 48 h were included. Propensity score matching (PSM) was performed at a 1:1 ratio to balance baseline variables. Logistic regression analyses were used to evaluate microbial clearance, clinical success, and acute kidney injury (AKI). Cox proportional hazards models assessed the 90-day all-cause mortality and factors associated with survival outcomes.Results Among the 106 LT recipients with postoperative CRO infections, 45 received CAZ/AVI (n = 23) or PMB (n = 22). After PSM, 22 patients were included in each group. The rates of microbial clearance (59.1% vs. 63.6%), clinical success (54.6% vs. 54.6%), and 90-day all-cause mortality (22.7% vs. 27.3%) were comparable between the CAZ/AVI and PMB (p > 0.05). However, AKI occurred significantly more frequently in the PMB group than in the CAZ/AVI group (81.8% vs. 50.0%, p = 0.026). Complete withdrawal of immunosuppressive therapy was independently associated with increased 90-day mortality (hazard ratio HR = 4.46, 95% CI 1.29–15.35, p = 0.018).Conclusion CAZ/AVI and PMB achieved similar clinical effectiveness and survival outcomes in LT recipients with CRO infections; however, PMB carries a higher risk of nephrotoxicity. Discontinuation of immunosuppressive therapy during infection significantly affects patient survival. These findings highlight the importance of individualised antimicrobial selection, renal safety monitoring, and pharmacist-led stewardship in managing CRO infections in liver transplant patients.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Zhang et al. (2026) studied this question.

synapsesocial.com/papers/69eb0803553a5433e34b336fhttps://doi.org/10.1080/20523211.2026.2641111
Ask AI
Helpful
Bookmark
Share
View Full Paper